Exetinib hydrochloride was included in the 2012 annual report of drug research and development

Source: Zhejiang Beida Pharmaceutical Co., Ltd., a member enterprise of China Council for the promotion of drugs, has made 10-year efforts to independently develop a new class 1.1 drug, comena hydrochloride, which was recently included in the annual review of drug R & D in 2012 The 2012 annual report on drug research and development was published by citeline, the world's largest clinical data provider Citeline is a network data provider that provides the world's most extensive online R & D intelligence for the pharmaceutical industry The data provided includes the unparalleled global clinical trial data collected by citeline, as well as the overview of researchers and drug analysis in research According to the report, 21 of the 33 new active substances first listed in the world in 2011 were in the United States, 3 in the United Kingdom and Japan, 2 in Germany and South Korea, and 1 in Switzerland, Denmark, China and the United Arab Emirates Cetinib hydrochloride, developed and listed by Zhejiang Beida Pharmaceutical Co., Ltd., is the first innovative drug independently developed by China, and one of the two anti-tumor drugs approved for the treatment of non-small cell lung cancer in 2011 (the other is Pfizer's clotinib) This proves that exetane hydrochloride, as the third EGFR-TKI (epidermal growth factor receptor tyrosine kinase inhibitor) drug in the world, has attracted worldwide attention and been recognized This also marks that the achievements of independent R & D projects supported by major new drug creation projects in China have been recognized by global authorities.